Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Asociación para Evitar la Ceguera en México

Status and phase: Terminated; Phase 3

Conditions: Choroidal Neovascularization; Angioid Streaks

Treatments: Drug: Intravitreal Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00599820

APEC 010

Details and patient eligibility

About

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Full description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Angioid Streaks
• Choroidal neovascularization associated
• Untreated patients or patients treated once with PDT

Exclusion criteria

• Ocular surgery excepting uncomplicated phacoemulsification
• Glaucoma or any other ocular pathology

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)